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Abstract
Background: We aimed to assess the positivity, distribution, quantitative degree of vessel inflammation, and clinical
characteristics of IgG4-related aortitis/periarteritis and periarteritis (IgG4-aortitis), and to examine the difference in
these characteristics between cases with and without IgG4-aortitis, using fluorodeoxyglucose positron-emission
tomography/computed tomography (FDG-PET/CT) co-registered with contrast-enhanced CT (CECT).
We retrospectively evaluated 37 patients with IgG4-related disease (IgG4-RD) who underwent both FDG-PET/CT
and CECT. The arterial SUVmax and its value normalized to the background venous blood pool (BP)—the target-
to-background ratio (TBR) in the entire aorta and the major first branches—were measured. Active vascular
inflammation was considered in cases with a higher FDG uptake than BP and a thickened arterial wall (>2 mm).
Results: Fifteen (41%) patients exhibited IgG4-aortitis. Most patients (80%) showed multiple region involvement.
The entire aorta, including the major first branches, were involved, typically showing a thickened wall and high
FDG uptakes. The most common site was the iliac arteries (35%), followed by the infrarenal abdominal aorta
(33%), thoracic aorta (8%), first branches of the thoracic aorta (8%), suprarenal abdominal aorta (6%), and the first
branches of the abdominal aorta (5%). The IgG4-aortitis-positive vessel regions were thickened, with an average
maximal wall thickness of 6.3 ± 2.9 mm. The SUVmax and TBR values were significantly higher in the IgG4-aortitis-
positive regions (median 3.7 [1.6–5.5] and 2.1 [1.4–3.7], respectively) than in the IgG4-aortitis-negative regions
(median 2.1 [1.2–3.7] and 1.3 [0.9–2.3], respectively; p < 0.0001). The IgG4-aortitis-positive group patients were
older (69.5 ± 6.0 vs. 63.3 ± 12.6 years, respectively) and had a higher male predominance (80 vs. 55%, respectively)
than the negative group, although the differences were not significant (p = 0.17 and p = 0.06, respectively).
Conclusions: We investigated the image characteristics of IgG4-aortitis. The entire aorta and major branches can
be involved with more than 2-fold higher FDG uptake than the venous background pool, and with wall
thickening. The most common involved site is the iliac arteries, followed by the infrarenal abdominal aorta.
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Background
Immunoglobulin G4-related disease (IgG4-RD) is a
newly recognized disease entity characterized by the
infiltration of IgG4-positive plasma cells and fibrosis in
systemic organs along with the elevation of serum IgG4
levels [1]. Autoimmune pancreatitis and Mikulicz’s
disease are representative phenotypes, and lymph node
swelling is a common finding in such cases. Moreover,
the pituitary gland, dura mater, orbital cavities, paranasal
sinuses, thyroid gland, breast, lung, liver, biliary system,
kidneys, prostate, retroperitoneum, and skin are poten-
tial targets for disease involvement [2–7].
Vascular involvement has also been detected in IgG4-RD
[8, 9]. The features of IgG4-related aortitis/periaortitis and
periarteritis (IgG4-aortitis) on computed tomography (CT)
include arterial wall thickening and homogeneous wall en-
hancement [4, 9]. The dissection of the great vessels and
myocardial ischemia due to coronary artery involvement
are fatal manifestations of IgG4-RD [10–19]. Nevertheless,
the prevalence, detailed distribution, and degree of inflam-
mation in IgG4-aortitis have not been reported.
In patients with IgG4-RD, whole-body organ involvement
manifests as increased FDG uptake in multiple organs on
fluorodeoxyglucose (FDG) positron-emission tomography
(PET) and FDG-PET/computed tomography (CT) [20–26].
Although histopathological examination remains the gold
standard for detecting organ involvement and diagnosing
IgG4-RD, it is difficult to obtain biopsy or surgical speci-
mens from the arterial wall. Hence, non-invasive evaluation
of vascular involvement is clinically important not only for
diagnosis but also for the management of IgG4-aortitis.
FDG-PET/CT has also been reportedly used to assess other
inflammatory vascular diseases, such as Takayasu arteritis
and giant cell arteritis [27, 28]. However, to our knowledge,
no study has described the use of systemic evaluation using
FDG-PET/CT co-registered with contrast-enhanced CT
(CECT) for IgG4-aortitis.
In the present study, we aimed to assess the positivity,
distribution, quantitative degree of vessel inflammation,
and clinical characteristics of IgG4-aortitis, and to exam-
ine the differences in these characteristics between cases




This retrospective study was approved by the institutional
review board. The requirement for obtaining informed
consent was waived. Forty-three patients who were
diagnosed with definite IgG4-RD according to the 2011
comprehensive diagnostic criteria for IgG4-RD proposed
by Umehara et al. [3] and who underwent FDG-PET/CT
and CECT within 3 months of diagnosis, from January
2009 to July 2015, were screened. Five patients who had
received steroid therapy prior to FDG-PET/CT and CECT
were excluded, and one patient was excluded because of
high serum glucose levels, exceeding 200 mg/dL. Hence,
37 patients were finally included in the study. It was con-
firmed that none of the patients had untreated or recur-
rent malignant disease during the follow-up period
(median 56 months, range 9–92 months).
The background of the patients is summarized in
Table 1. The median patient age was 68 years (range
39–83 years), and 24 patients were male. The median
interval between the applications of the two modalities
was 13 days (range 1–88 days). All patients underwent
biopsy or surgery, and 22 patients exhibited IgG4-positive
plasma cell infiltration. There were 15 patients with
negative histopathological diagnoses. However, eight of
these patients were diagnosed according to the Clinical
Diagnostic Criteria for Autoimmune Pancreatitis of Japan
2006 [29], and the other seven patients were diagnosed
according to the Diagnostic Criteria for IgG4-positive
Mikulicz’s disease [30]. All patients showed abnormal in-
creases in serum IgG4 levels, exceeding 135 mg/dL, except
for one (patient #17) with normal IgG4 levels diagnosed
as having definite IgG4-RD according to the Clinical
Diagnostic Criteria for Autoimmune Pancreatitis of Japan
2006 [29].
The serum IgG4 levels within 2 months from PET/CT
were available in 28 patients.
Imaging techniques
FDG-PET/CT was performed using a hybrid scanner
(Biograph 64 with TrueV and high-definition PET,
Siemens Japan, Tokyo, Japan), with lutetium oxyorthosi-
licate crystal detectors, covering an axial field of view of
21.6 cm, and a 64-slice multi-detector computed tomog-
raphy scanner. The patients were instructed to fast for
more than 6 h, and their blood glucose level was mea-
sured (median blood glucose level, 101 mg/dL; range
79–182 mg/dL) before injecting the FDG. A mean total
dose of 240 ± 35 MBq of the FDG was administered
intravenously, which was computed as 4.2 ± 0.6 MBq/kg.
Following the injection, the patient was allowed to rest
comfortably for 60 min. Image acquisition was initiated
with a non-contrast-enhanced CT scan for attenuation
correction and co-registration. This was followed by
three-dimensional PET acquisition, with a 3-min
time-limit per position, from the top of the skull to
the mid-thigh.
Standard diagnostic CT scans were performed with a
64-multislice CT scanner (Aquilion 64, Aquilion PRIME,
or Aquilion One ViSION edition, Toshiba Medical
Systems, Otawara, Japan; LightSpeed VCT, GE Health-
care, Milwaukee, WI, USA; or SOMATOM Sensation
64, Siemens AG Medical Solutions, Erlangen, Germany).
The CECT protocol in the present study included a
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single-phase scan performed from the neck to the
pelvis, 70–180 s after the injection of contrast mater-
ial (450–560 mg·I/kg), with a 5-mm section thickness.
Imaging analysis
Vascular involvement was assessed at the following six
regions: thoracic aorta, suprarenal abdominal aorta,
Table 1 Patient characteristics












1 79 F Definite Pancreas 38 N/A + LN, SG, P
2 75 M Definite Minor salivary gland 7 953 + LN
3 61 M Definite Minor salivary gland, bile duct 7 968 + LN
4 70 M Definite Gall bladder 9 802 + LN, P
5 67 M Definite Nasal mucosa 1 1390 + LN, SG, C
6 73 M Definite Bile duct 17 1370 + LN, SG, C, P
7 74 M Definite Lung 21 384 + LN, SG, C
8 61 F Definite Pancreas 12 149 + LN, SG, P
9 71 M Definite − 43 N/A + LN, P
10 77 M Definite − 6 N/A + LN
11 69 M Definite − 6 733 + LN, SG
12 71 M Definite − 8 469 + LN, SG, P
13 68 F Definite − 13 571 + LN, P
14 68 M Definite − 28 877 + LN, SG, C, P
15 58 M Definite − 12 326 + LN, SG, P
16 78 M Definite Abdominal aorta 3 225 − P
17 77 M Definite Bile duct 8 89.8 − LN, P
18 54 M Definite Nasal mucosa, bile duct 6 455 − LN, SG, P
19 73 F Definite Lacrimal gland 28 N/A − LN
20 55 F Definite Minor salivary gland 80 N/A − SG
21 60 F Definite Nasal mucosa 26 N/A − LN, SG
22 78 M Definite Minor salivary gland, nasal mucosa 11 888 − LN, SG
23 50 M Definite Nasal mucosa 5 408 − LN, P
24 67 M Definite Nasal mucosa 13 377 − a
25 51 F Definite Lacrimal gland 1 398 − LN, SG
26 45 M Definite Submandibular gland 20 N/A − LN, C
27 83 M Definite Minor salivary gland 49 905 − LN, SG
28 78 F Definite Pancreas 31 243 − LN, P
29 39 F Definite Lymph node 3 479 − LN, SG
30 75 M Definite − 88 N/A − b
31 73 F Definite − 56 N/A − LN, SG
32 66 M Definite − 32 N/A − C
33 59 F Definite − 8 N/A − LN, SG, C, P
34 67 M Definite − 33 526 − C, P
35 60 M Definite − 23 862 − LN, SG
36 46 F Definite − 30 797 − LN, SG
37 58 F Definite − 60 977 − LN, SG
Y year, d days, M male, F female, + positive, − negative, N/A not available, LN lymph node, SG salivary gland, C chest (pleura/paravertebra), P pancreas
a(Patient no. 24) A patient with small hypovascular lesions in the bilateral kidney on CECT; the FDG-PET/CT findings could not be assessed due to physiological
uptake by the renal parenchyma. This patient was treated for IgG4-RD
b(Patient no. 30) A patient with abnormal pancreas findings on CECT, without significant abnormal FDG uptake. The patient was diagnosed as having autoimmune
pancreatitis using endoscopic retrograde cholangiopancreatography
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infrarenal abdominal aorta, iliac arteries (common,
external, and internal iliac arteries), first branches of the
thoracic aorta (brachiocephalic, left common carotid,
and left subclavian arteries), first branches of the abdom-
inal aorta (celiac, superior mesenteric, renal, and inferior
mesenteric arteries).
Of the 222 vascular regions in 37 patients, 220 regions
were evaluated; two regions could not be assessed due to
suprarenal and infrarenal aortic replacement. Below the
kidney level, abnormal vessel FDG uptake was differenti-
ated from uptake in the urinary tract using co-registered
CECT images (Fig. 1).
FDG-PET/CT and CECT images were simultaneously
reviewed by two board-certified radiologists (one with
10 years of radiology experience and another with
20 years of experience and a certification in nuclear
medicine) in consensus.
The diagnostic criteria for CECT were based on the
findings of a previous study [4, 9, 31, 32]. For active in-
flammatory arteritis, abnormal diffuse arterial wall thick-
ening (>2.0 mm) [31] and homogeneous enhancement
on CECT [4, 9, 32] were considered to indicate positive
involvement. Since IgG4-aortitis revealed severe inflam-
matory cell infiltration, mainly into the adventitia [9],
the maximal radial vessel wall thickness measurement
was carefully performed in such a way as to avoid
including intimal atherosclerotic calcification. The pres-
ence of aneurysmal changes or dissection was recorded,
and maximum wall thickness was measured on CECT
axial images.
The diagnostic criteria of the FDG-PET/CT were
based on visual evaluation of a higher abnormal vessel
wall uptake than that in the blood pool. For qualitative
evaluation, the vessel standardized uptake value (SUV-
max) of each vascular region was defined as the maximal
value by drawing several volumes of interest (VOIs) with
a radius of 5 mm. For normalizing the SUVmax value,
we also calculated the ratio of the arterial SUVmax to
that of the venous blood pool, also known as the target-
to-background ratio (TBR). Rudd et al. described the
TBR as a reproductive and quantitative method for
assessing the arterial wall [33]. Besson et al. reported the
utility of TBR for the assessment of aortic inflammation
in giant cell arteritis patients [34]. With regard to the
background, the VOIs in the inferior vena cava and right
atrium were also measured. The SUVmax of the back-
ground venous blood pool was calculated as the mean
value of the SUVmax at the right atrium and inferior
vena cava.
When abnormal findings were simultaneously detected
on both CECT and FDG-PET/CT images, the region was
considered to have positive inflammation due to IgG4-
aortitis (IgG4-aortitis-positive region). IgG4-aortitis was
differentiated from atherosclerosis as follows: if there was
an abnormal finding only with CECT or FDG-PET/CT, or
if there was no abnormal finding on both CECT and
FDG-PET/CT, the region was considered as IgG4-aortitis-
negative region. This sorting was applied to six regions
independently in each patient. If a patient had at least one
positive vascular region, the patient was assigned to the
IgG4-aortitis-positive group. Patients without vascular in-
volvement were assigned to the IgG4-aortitis-negative
group. The involvement of other organs, such as lymph
node, salivary gland, pancreas, and chest (pleura and
paravertebral region) were simultaneously assessed. The
diagnostic clue for lymph node involvement is abnormal
swelling and diffuse enhancement. The salivary gland
shows unilateral or bilateral diffuse or focal swelling and
homogeneous enhancement. The pancreas shows diffuse
or focal enlargement with irregular narrowing and loss of
the pancreatic cleft and smooth rim (capsule-like rim).
Pleural and paravertebral involvements are indicated by
thickened or flattened soft tissue density areas along the
pleura and vertebra [4, 5, 32, 35]. The lacrimal gland and
paranasal sinuses were not assessed, since the scanning
range of whole-body CECT did not include it in all cases.
Fig. 1 CECT (a) and FDG-PET/CT (b) images demonstrating left
internal iliac artery involvement (white arrow). Physiological uptake
by the urinary tracts (black arrows) cannot be differentiated using
FDG-PET/CT alone
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The kidneys could not be assessed due to the physiological
uptake in the renal parenchyma.
Statistical analysis
To evaluate the disease distribution, the positivity ratio
was calculated for each of the six regions.
We compared the differences in the patient’s back-
ground (including sex, age, prevalence of diabetes
mellitus, and serum IgG4 level) between the IgG4-aortitis-
positive and IgG4-aortitis-negative groups. The categorical
variables, including male-to-female ratio and diabetes
mellitus, were compared using Fisher’s exact test. An un-
paired Student t test was used to compare the continuous
variables with normal distribution, including age and
serum IgG4 levels, between the two groups.
For region-based comparisons, the vessel SUVmax
and TBR values were compared between the IgG4-
aortitis-positive and IgG4-aortitis-negative regions. Since
the vessel SUVmax and TBR values were not normally
distributed, they were compared using the nonparametric
Wilcoxon rank-sum test.
Continuous variables are presented as mean ± standard
deviation or as median (range), whereas categorical
variables are presented as percentages. A p value <0.05
was considered significantly different.
All statistical analyses were performed using dedicated
software JMP 12.2.0 (SAS institute, Cary, NC, USA).
Results
Positivity, distribution, and clinical characteristics of
IgG4-aortitis
Fifteen of 37 patients (41%) had at least one positive
IgG4-aortitis-positive region and were assigned to the
IgG4-aoritis-positive group (Table 1); among these pa-
tients, three (20%) exhibited vascular involvement at a
single site and 12 (80%) exhibited vascular involvement
at multiple sites. A total of 35 IgG4-aortitis-positive re-
gions were detected, and the average number of positive
vessels per patient was 2.3. The detailed distribution,
maximal wall thickness, and vessel TBR of the IgG4-
aortitis-positive regions in these 15 patients are summa-
rized in Table 2.
Figure 2 shows the positivity in each of the six vascular
regions. Thirteen of 37 patients (35%) exhibited iliac
artery involvement, which was the most common site,
followed by the infrarenal abdominal aorta (33%), thor-
acic aorta (8%), first branches of the thoracic aorta (8%),
suprarenal abdominal aorta (6%), and first branches of
the abdominal aorta (5%).
The IgG4-aortitis-positive vessel regions were thickened,
with an average maximal wall thickness of 6.3 ± 2.9 mm.
Ten (27%) of 37 patients showed aneurysmal aortic dilata-
tions. Nine of 37 patients (24%) exhibited aneurysmal
changes in the iliac arteries, and four patients (11%)
exhibited abdominal aortic aneurysms, while three
patients showed overlaps between these regional involve-
ments. There was no case of aortic dissection. A represen-
tative case with abdominal aorta involvement is described
in Fig. 3.
The IgG4-aortitis-positive group was older (69.5 ± 6.0
vs. 63.3 ± 12.6 years, respectively) and had a higher male
predominance (80 vs. 55%, respectively) than those in
the negative group, although the differences were not
significant (p = 0.17 and p = 0.06, respectively). There
was no significant difference in the incidence of diabetes
mellitus between the groups (40 vs. 23%; p = 0.22). The
mean serum IgG4 levels (749 ± 392 mg/dL) in the IgG4-
aortitis-positive group were higher than those in the
IgG4-aortitis-negative group (545 ± 288 mg/dL), although
the difference was not significant (p = 0.15).
Quantification of inflammation in IgG4-aortitis
The median vessel SUVmax value in the IgG4-aortitis-
positive regions (3.7; range, 1.6–5.5) was significantly
higher than that in the IgG4-aortitis-negative regions
(2.1; range, 1.2–3.7; p < 0.0001; Fig. 4).
The median TBR value in the IgG4-aortitis-positive
regions (median, 2.1; range, 1.4–3.7) was significantly
higher than that in the IgG4-aortitis-negative regions
(median, 1.3; range, 0.9–2.3; p < 0.0001; Fig. 5).
Discussion
In the present study, we assessed the positivity, distribu-
tion, quantitative degree of vessel inflammation, and
clinical characteristics of IgG4-aortitis, and examined the
differences in these characteristics between cases with and
without IgG4-aortitis using FDG-PET/CT co-registered
with CECT. To our knowledge, a detailed systemic assess-
ment of IgG4-aortitis with FDG-PET/CT and CECT has
not been reported to date. Approximately, 40% of IgG4-
RD patients exhibited vascular involvement, with a high
SUVmax and TBR value (median, 3.7 and 2.1, respect-
ively) and wall thickening (median, 6.3 mm). IgG4-
aortitis-positive regions exhibited more than 2-fold the
FDG uptake of the background blood pool (median, 3.7
vs. 1.6). The typical finding of IgG4-aortitis-positive group
was multiple vascular region involvements (80%). The en-
tire aorta and major branches can be involved with more
than 2-fold the FDG uptake of the venous background
pool. The most common site was the iliac arteries,
followed by the infrarenal abdominal aorta.
To assess IgG4-RD, modalities such as CT, magnetic res-
onance imaging, ultrasonography, Gallium-67 scintigraphy,
endoscopic retrograde cholangiopancreatography, endo-
scopic ultrasonography, intraductal ultrasonography, and
FDG-PET or FDG-PET/CT have been used individually or
in combination for both morphological and functional
evaluation [2, 32, 36–39]. Some authors have reported the
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clinical applicability of FDG-PET/CT as a single modality
in IgG4-related autoimmune pancreatitis [23, 40]. How-
ever, FDG uptake is non-specific for vascular evaluation
and does not always allow differentiation between athero-
sclerotic changes and active inflammation [41, 42]. As
vascular involvement is more commonly observed in older
male patients, it is clinically important to differentiate
Fig. 2 Whole body distribution and positivity of vascular involvement.
Fifteen patients exhibited vascular involvements in 35 regions
Fig. 3 A 75-year-old man with involvement of the abdominal aorta
(case #2). MIP image (a) showing multiple organ involvement,
including hilar lymph node, abdominal aorta, and the left iliac artery
(white arrows). FDG PET/CT fusion image (b) and CECT (c) exhibiting
marked wall thickening of the abdominal aorta and abnormal FDG
uptake (white arrow). Note the physiological uptakes in the bilateral
urinary tract (black arrows)
Table 2 Summary of vascular lesions





TA Suprarenal AA Infrarenal AA IA TA-branch AA-branch
1 − − − 2.7 − 3.6a 7.9 2
2 − − 3.7 2.8a − − 9.8 2
3 − − 1.6a 1.6 − − 3.0 2
4 − − 2.6a 2.2 1.8 − 4.7 3
5 − − 2.0a 1.7 − − 3.1 2
6 − − 1.4 2.0a − − 6.1 2
7 − − 2.1a 2.3 − − 4.4 2
8 − − − 2.6a − − 3.9 1
9 − 2.2 2.7a 1.8 3.0 − 11.3 4
10 1.5a − 2.1 2.1 − − 4.3 3
11 2.0 2.4 2.4 2.1 1.4a − 5.8 5
12 − − 1.5 1.7a − − 8.1 2
13 − − − − − 1.7a 2.5 1
14 1.7 − 2.6a 2.2 − − 11.1 3
15 − − 2.3a − − − 8.1 1
Average 1.7 2.3 2.3 2.1 2.1 2.7 6.3 2.3
TBR target-to-background ratio, AA abdominal aorta, IA iliac arteries, TA thoracic aorta, − negative
aRegion of the maximal wall thickness
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between IgG4-aortitis and atherosclerosis. Although the
evaluation of vessel wall thickness on CECT may serve as
a good predictor of vascular inflammation [9, 31],
increased wall thickness can persist for a long time after
the acute phase of arterial inflammation, thus limiting its
relevance in the early assessment of inflammation. There-
fore, we investigated the usefulness of a combination
of quantitative vessel SUVmax/TBR on FDG-PET/CT
and anatomical abnormal wall thickening on CECT. Rudd
et al. reported that the mean and maximum TBR values
were reproducible and optimal for evaluation of the arterial
FDG uptake [33]. Hence, TBR could add to the diagnostic
performance, which currently includes visual assessment
alone, and may be particularly useful for differentiation
from atherosclerosis. Combining the metabolic informa-
tion from FDG-PET/CT with the thickened vessel wall
data from co-registered CECT could be a powerful method
for evaluating inflammatory IgG4-aortitis. Moreover, the
quantitative vessel SUVmax and TBR values may reduce
observer bias as compared to that noted with visual quali-
tative evaluation of vascular involvement.
Previous studies have reported the prevalence of vas-
cular involvement as 14–23% [24, 25, 32, 43]. However,
these studies did not use specific quantitative analysis
for active inflammation of the aorta, and the diagnostic
criteria for IgG4-aortitis were also not clearly defined.
Moreover, these studies did not differentiate between
atherosclerosis and IgG4-aortitis. In our study, we quan-
tified abnormal vascular FDG uptake, co-registered with
CECT, to differentiate the condition from atherosclerosis
or physiological uptake, such as that noted in the urinary
tracts. Combination of FDG-PET and CECT may have led
to a relatively higher prevalence (41%) of IgG4-aortitis in
the present study than in previous reports.
There have been two previous studies that reported
the distribution of IgG4-aortitis. Inoue et al. reported
that 13 (76%) of 17 patients had infrarenal abdominal
aorta or iliac arteries involvement, while the thoracic
aorta was involved only in four patients (24%) [9]. This
result was concordant with our result. On the other
hand, the distribution in a report by Perugino et al. was
different [44]. In their 13 patients, eight patients (62%)
had thoracic aorta, four patients (31%) with abdominal
aorta, and one patient (8%) with iliac artery involvement.
The reason for this discrepancy is not clear; however,
racial differences may potentially influence the result.
Some form of aneurysmal change was observed in the
aortas of 10 patients (27%) in our study, while Perugino
et al. reported that 11 of 160 (7%) patients demonstrated
thoracic or abdominal aortic aneurysms [44]. These data
revealed that IgG4-aortitis carried the potential risk of
aortic aneurysm. Although the risk of aortic rupture is
unclear, there was no case of dissection in our study.
Mizushima et al. reported that a small population of pa-
tients with IgG4-aortitis exhibited luminal dilatation
after corticosteroid therapy [45]. Hence, patients with
IgG4-aortitis should be carefully followed before and
after steroid therapy.
In our study, patients with IgG4-aortitis tended to be
older and male as compared to those in the negative
group, which was also consistent with the previous
report [44].
The present study has certain limitations. First, the
study design was retrospective in nature, which may
have led to possible selection bias and the restriction of
evaluable regions. Moreover, we included only newly
diagnosed patients, who had not been exposed to
immunosuppressive treatments, and hence, not all the
patients diagnosed with IgG4-RD were enrolled in this
study. Second, the evaluable region may have been re-
stricted due to the non-ECG-gated body CECT scanning
protocol; hence, we could not evaluate the head and
neck region, and particularly the carotid arteries. The
Fig. 5 Comparisons of TBR values between patient regions with and
without vascular involvement
Fig. 4 Comparisons of the highest SUVmax values between regions
with and without vascular involvement
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coronary arteries were also not evaluated due to motion
artefacts. Third, FDG-PET/CT and CECT images were
simultaneously reviewed for division into IgG4-aortitis-
positive and IgG4-aortitis-negative regions. Because both
a thickened arterial wall on CECT and a higher uptake
of FDG in the visual assessment were used for deter-
mining IgG4-aortitis-positivity, there was a potential
bias that the positive region would show a higher
SUVmax value. The IgG4-aortitis-positive region may
include both active inflammation and atherosclerosis;
however, our aim was not to differentiate active inflamma-
tion from atherosclerosis, but to examine the degree of
FDG uptake in active regions. Finally, we did not perform
biopsies for vascular involvement, as there is no patho-
logical gold standard for diagnosis. Moreover, it is difficult,
and may not be safe, to obtain vessel wall specimens.
Hence, a non-invasive method is required for the diagno-
sis of IgG4-aortitis.
Conclusions
We assessed the positivity and distribution of vascular in-
volvement in IgG4-RD using FDG-PET/CT co-registered
with CECT. The entire aorta and major branches may
be involved, with more than twice the FDG uptake as
compared to the venous blood pool. The infrarenal
abdominal aorta and iliac arteries were the most com-
monly involved sites.
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